Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141194 | 0.84 | CYP2C9 (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL3175714 | 0.83 | HSD17B3 (0.72) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8745753 | 0.81 | NQO1 (0.61) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL18766190 | 0.81 | KDM4E (0.60) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29699265 | 0.81 | KDM4E (0.60) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL7141692 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29944843 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL24627780 | 0.78 | MAPT (0.72) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8745770 | 0.76 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL22733326 | 0.76 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095032-B1 | REAGENTS FOR CYP2D FLUORESCENT ASSAY | GENTEST CORP (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1095032-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2001-05-02 | — | — | EP | claimed |
| US-6130342-A | A 2-OXOCHROMAN COMPOUND CONTAINING A QUATERNARY AMINE GROUP | GENTEST CORPORATION (US) | 2000-10-10 | — | — | US | claimed |
| WO-2000004008-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2000-01-27 | — | — | WO | claimed |
| EP-4379062-A1 | BIOSYSTEM FOR PESTICIDE DETECTION | Fundación AZTI - AZTI Fundazioa (ES) | 2024-06-05 | — | — | EP | disclosed |
| US-20240175069-A1 | BIOSYSTEM FOR PESTICIDE DETECTION | Fundación AZTI – AZTI Fundazioa (ES) | 2024-05-30 | — | — | US | disclosed |
| US-20240150297-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024064178-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2022266394-A9 | NOVEL ISOMEROHYDROLASE INHIBITOR FOR TREATMENT OF ATROPHIC FORM OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4291191-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4271830-A1 | BIOSYSTEMS TO DETECT CHEMICAL CONTAMINANTS | Fundacion Azti/Azti Fundazioa (ES) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20030054974-A1 | Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof | ARYX THERAPEUTICS | 2003-03-20 | — | — | US | disclosed |
| WO-2003017946-A2 | NON-OXIDATIVELY METABOLIZED COMPOUNDS AND COMPOSITIONS, SYNTHETIC PATHWAYS THEREFOR, AND USES THEREOF | ARYX THERAPEUTICS (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| US-20020045620-A1 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2002-04-18 | — | — | US | disclosed |
| WO-2002024689-A1 | ISOXAZOLIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1095032-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6130342-A | A 2-OXOCHROMAN COMPOUND CONTAINING A QUATERNARY AMINE GROUP | GENTEST CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000004008-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054974-A1 | Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof | CYP11B1, CYP11B2, CYP27A1 | KDM4E 3972/4885ALDH1A1 241/4885HPGD 79/4885 |
| US-20020045620-A1 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals | LIPA, PNLIP, PCSK9 | KDM4E 1894/4885ALDH1A1 423/4885HPGD 518/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | KDM4E 4275/4885ALDH1A1 2655/4885HPGD 4771/4885 |
| US-20240150297-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, APOB, TSHR | KDM4E 4425/4885ALDH1A1 2564/4885HPGD 4617/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | KDM4E 2728/4885ALDH1A1 525/4885HPGD 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.